Amgen's Lumakras (sotorasib) Receives the US FDA's Approval as the First KRAS Blocking Cancer Therapy
Shots:
- The approval is based on the CodeBreaK 100 trial evaluating the efficacy & tolerability of Lumakras (960mg- qd) in 124 patients with KRAS G12C mutation-positive NSCLC whose disease had progressed after prior treatment with immunotherapy or CT
- Results: ORR (36%); DCR (81%); mDoR (10 mos.); durable response with a positive benefit-risk profile- 9% showed permanent discontinuation due to AEs
- The company is conducting biomarker testing & a patient support program for NSCLC. The therapy is also being studied in multiple other solid tumors
Ref: PRNewswire | Image: BioSpace
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com